-
Media ReleaseNovartis shareholders approve the proposed 100% Spin-off of Sandoz
-
Media ReleaseLes actionnaires de Novartis approuvent le projet de scission à 100% de Sandoz
-
Media ReleaseAktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
-
Media ReleaseSandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
-
Story
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way -
Media ReleaseNovartis nomme Patrick Horber, Docteur en médecine, au poste de President, International, alors que Marie-France Tschudin, President, Innovative Medicines International et Chief Commercial Officer, quitte le Comité exécutif de Novartis
-
Media ReleaseNovartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis
-
Media ReleaseNovartis ernennt Dr. Patrick Horber zum President, International, da Marie-France Tschudin, President, Innovative Medicines International und Chief Commercial Officer, aus der Geschäftsleitung von Novartis ausscheidet
-
Media ReleaseNovartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
-
Media ReleaseNovartis completes acquisition of Chinook Therapeutics
-
Media ReleaseNovartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
-
Media ReleaseNovartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz¹˒²